Uses spatial omics and AI-driven computational pathology to identify molecular signatures of diseases, enabling the development of precision therapeutics tailored to individual patients. This approach targets both rare and common diseases by uncovering biomarkers that guide treatment and monitor disease progression.
Funding
Funding not disclosed
Founders
Product
Problem
Current methods for identifying effective therapeutic targets and monitoring disease activity in both rare and common diseases often lack the precision needed for personalized treatment strategies. Traditional approaches may fail to capture the complex interplay of molecular factors within specific tissue microenvironments, hindering the development of targeted therapies.
Solution
SygnaMap employs spatial omics and AI-driven computational pathology to map and analyze the spatial distribution of molecules within tissue samples, revealing critical pathways underlying disease pathologies. By integrating single-cell mass spectrometry data with advanced computational algorithms, SygnaMap identifies key molecular signatures and biomarkers that can guide the development of precision therapeutics. This approach enables the resolution of complex diseases into actionable insights, facilitating the creation of patient-specific therapies and the monitoring of treatment efficacy through predictive biomarkers. The platform aims to optimize therapeutic choices, reduce adverse effects, and ultimately drive better patient outcomes.
Target Audience
SygnaMap's primary customers are biotechnology researchers and pharmaceutical companies focused on developing precision therapeutics for both rare and common diseases.
Features
- Spatial omics analysis to map the distribution of molecules within tissue microenvironments.
- AI-driven computational pathology for identifying disease signatures.
- Single-cell mass spectrometry technologies to identify small molecules regulating cellular neighborhoods.
- Advanced computational algorithms to correlate spatial omics data with disease phenotypes.
- Identification of predictive biomarkers for guiding therapeutic targets.
- Patient-centric approach to enable highly effective, patient-specific therapies.